

PRESS RELEASE



Mr RICHARD GUILLAUME IS APPOINTED TO THE DIAFIR BOARD OF DIRECTORS

RENNES, FRANCE — March, 29 2019 — DIAFIR, a medical technology company focused on the development, manufacture and sale of innovative diagnostic solutions in nonalcoholic steatohepatitis (NASH) and septic arthritis announces today the appointment of Mr Richard Guillaume to its Board of Directors

Mr Guillaume has a wide experience of over 30 years in international management and operations in the pharmaceutical industry as well as in the medtech. Drawing on his experience and knowledge in the field of medical devices and diagnosis, Mr Guillaume will advise and help the Company in its development.

Alongside his role at Diafir, Richard Guillaume has been the General Manager of Echosens from 2008 until 2013. He was previously Executive Vice President Global Sales and Marketing at Blatchford, a UK medical device company. He was also member of the board. Prior, he held various positions such as Director Global Marketing of Abbott International in Chicago and Director Category Development Europe of Mead Johnson. Richard holds a Master in Business Administration from Poitiers University and a DESS in Marketing from Paris Dauphine completed by a general management program at INSEAD.

Hugues Tariel, Founder and CEO of DIAFIR, said: *“We are delighted to welcome Richard as a Diafir board member. His vision and experience will be a great addition to our team, to ensure SPID™ platform success for NASH in hepatology and more broadly as an accurate, fast and versatile diagnostic tool.”* **Richard Guillaume**, declared: *“I’m pleased to join the board of Diafir who is developing a new innovative in vitro diagnostic technology to improve patient quality of life».*

ABOUT DIAFIR

DIAFIR is a medical technology company with expertise in developing innovative in vitro diagnostic tests to improve the detection and monitoring of patients with nonalcoholic steatohepatitis (NASH) and septic arthritis. Diafir’s technology relies on mid-infrared analysis of the metabolic signature of patients using the SPID™ platform, which allows for low-invasive, cost-effective and rapid diagnostic procedures. DIAFIR aims to improve patient care management by bringing its diagnostic tests to the front line in order to detect and track all potential patients with NASH and septic arthritis.

Contact DIAFIR :

Hugues TARIEL

Chief Executive Officer

info@diafir.com

+33 (0)2 99 67 15 41

www.diafir.com